This report concludes that the evidence is too weak to demonstrate either greater efficacy of brachytherapy compared to other treatments or better cost-effectiveness. However, complications appear to be much less frequent with brachytherapy. In summary, this technology remains experimental until data are available to confirm its efficacy, particularly among men with localised, well-differentiated early stage prostate cancer with low pre-treatment PSA levels.